James G. Christensen

45.8k total citations · 8 hit papers
189 papers, 18.5k citations indexed

About

James G. Christensen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James G. Christensen has authored 189 papers receiving a total of 18.5k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 92 papers in Molecular Biology and 77 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James G. Christensen's work include Lung Cancer Treatments and Mutations (49 papers), Liver physiology and pathology (39 papers) and PI3K/AKT/mTOR signaling in cancer (35 papers). James G. Christensen is often cited by papers focused on Lung Cancer Treatments and Mutations (49 papers), Liver physiology and pathology (39 papers) and PI3K/AKT/mTOR signaling in cancer (35 papers). James G. Christensen collaborates with scholars based in United States, South Korea and Australia. James G. Christensen's co-authors include Pasi A. Jänne, John M.L. Ebos, Christina R. Lee, Robert S. Kerbel, Ravi Salgia, Georg A. Bjarnason, William Cruz‐Muñoz, Andrew M. Rogers, Jeffrey A. Engelman and Kreshnik Zejnullahu and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

James G. Christensen

183 papers receiving 18.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 3.6k citations Kreshnik Zejnullahu, James G. Christensen et al. profile →
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

2009 1.4k citations James G. Christensen et al. profile →
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

2010 604 citations James E. Butrynski, Marzia Capelletti et al. profile →
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

2007 593 citations Helen Y. Zou, Qiuhua Li et al. Cancer Research profile →
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

2007 513 citations James G. Christensen, Helen Y. Zou et al. Molecular Cancer Therapeutics profile →
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

2016 493 citations Pasi A. Jänne, James G. Christensen et al. profile →
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

2022 269 citations James G. Christensen et al. profile →
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^G12C Solid Tumors (KRYSTAL-1)

2022 206 citations Pasi A. Jänne, Joshua K. Sabari et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James G. Christensen United States	61	9.8k	9.0k	7.7k	3.7k	3.3k	189	18.5k
Brian Schwartz United States	47	7.7k 0.8×	5.2k 0.6×	5.8k 0.8×	3.3k 0.9×	2.3k 0.7×	143	14.4k
Fairooz F. Kabbinavar United States	54	7.8k 0.8×	12.9k 1.4×	8.8k 1.1×	4.1k 1.1×	3.4k 1.0×	175	21.8k
William Novotny United States	38	8.0k 0.8×	12.5k 1.4×	5.7k 0.7×	3.8k 1.0×	3.0k 0.9×	110	22.6k
Eric Holmgren United States	24	4.8k 0.5×	8.7k 1.0×	4.4k 0.6×	2.5k 0.7×	2.3k 0.7×	46	14.1k
Federico Cappuzzo Italy	63	7.0k 0.7×	16.9k 1.9×	16.9k 2.2×	4.3k 1.2×	1.3k 0.4×	360	24.6k
David R. Spigel United States	68	5.0k 0.5×	14.4k 1.6×	9.9k 1.3×	2.9k 0.8×	1.0k 0.3×	611	20.0k
Johanna C. Bendell United States	63	5.4k 0.6×	9.4k 1.0×	4.3k 0.6×	2.1k 0.6×	938 0.3×	535	14.8k
Lucio Crinò Italy	67	5.5k 0.6×	13.5k 1.5×	13.4k 1.7×	3.3k 0.9×	855 0.3×	372	19.4k
Sabine Tejpar Belgium	53	3.7k 0.4×	11.3k 1.3×	4.3k 0.6×	3.3k 0.9×	2.1k 0.6×	214	15.5k
Neal I. Lindeman United States	49	8.1k 0.8×	11.6k 1.3×	13.2k 1.7×	5.8k 1.6×	639 0.2×	172	22.4k

Countries citing papers authored by James G. Christensen

Since Specialization

Citations

This map shows the geographic impact of James G. Christensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James G. Christensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James G. Christensen more than expected).

Fields of papers citing papers by James G. Christensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James G. Christensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James G. Christensen. The network helps show where James G. Christensen may publish in the future.

Co-authorship network of co-authors of James G. Christensen

This figure shows the co-authorship network connecting the top 25 collaborators of James G. Christensen. A scholar is included among the top collaborators of James G. Christensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James G. Christensen. James G. Christensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sabari, Joshua K., Vamsidhar Velcheti, K. Shimizu, et al.. (2022). Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 28(15). 3318–3328. 78 indexed citations

Wang, Kai, Qin Zhang, Danan Li, et al.. (2015). PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor. Clinical Cancer Research. 21(6). 1487–1496. 122 indexed citations

Zhang, Ying, Yanzhi Yang, Fadila Guessous, et al.. (2013). Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition. Clinical Cancer Research. 19(6). 1433–1444. 29 indexed citations

Pavlı́c̀ek, Adam, Maruja E. Lira, Nathan V. Lee, et al.. (2013). Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871). Molecular Cancer Therapeutics. 12(12). 2929–2939. 31 indexed citations

Sennino, Barbara, Toshina Ishiguro‐Oonuma, Brian J. Schriver, James G. Christensen, & Donald M. McDonald. (2013). Inhibition of c-Met Reduces Lymphatic Metastasis in RIP-Tag2 Transgenic Mice. Cancer Research. 73(12). 3692–3703. 48 indexed citations

Hook, Kenneth E., Maruja E. Lira, Keith A. Ching, et al.. (2012). An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735. Molecular Cancer Therapeutics. 11(3). 710–719. 77 indexed citations

Zhang, Cathy C., Adam Pavlı́c̀ek, Qin Zhang, et al.. (2012). Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models. Clinical Cancer Research. 18(18). 5008–5019. 53 indexed citations

Zou, Helen Y., Qiuhua Li, Joseph H. Lee, et al.. (2012). Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor. Molecular Cancer Therapeutics. 11(4). 1036–1047. 57 indexed citations

Cortot, Alexis B., Claire E. Repellin, Takeshi Shimamura, et al.. (2012). Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. Cancer Research. 73(2). 834–843. 163 indexed citations

10.

Zhang, Cathy C., Zhengming Yan, Wenlin Li, et al.. (2011). [18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells. Clinical Cancer Research. 18(5). 1303–1312. 62 indexed citations

11.

Kinross, Kathryn M., Daniel V. Brown, Margarete Kleinschmidt, et al.. (2011). In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D ; Pten Deletion Mouse Model of Ovarian Cancer. Molecular Cancer Therapeutics. 10(8). 1440–1449. 62 indexed citations

12.

Shojaei, Farbod, Joseph H. Lee, Brett H. Simmons, et al.. (2010). HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors. Cancer Research. 70(24). 10090–10100. 267 indexed citations

13.

Sasaki, Takaaki, Katsuhiro Okuda, Wei Zheng, et al.. (2010). The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers. Cancer Research. 70(24). 10038–10043. 254 indexed citations

14.

Murray, Brion W., Chuangxing Guo, Joseph Piraino, et al.. (2010). Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proceedings of the National Academy of Sciences. 107(20). 9446–9451. 253 indexed citations

15.

McDermott, Ultan, Raju V. Pusapati, James G. Christensen, Nathanael S. Gray, & Jeff Settleman. (2010). Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency. Cancer Research. 70(4). 1625–1634. 129 indexed citations

16.

Seiwert, Tanguy Y., Ramasamy Jagadeeswaran, Leonardo Faoro, et al.. (2009). The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. Cancer Research. 69(7). 3021–3031. 211 indexed citations

17.

McDermott, Ultan, A. John Iafrate, Nathanael S. Gray, et al.. (2008). Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors. Cancer Research. 68(9). 3389–3395. 312 indexed citations

18.

Christensen, James G., Helen Y. Zou, Maria E. Arango, et al.. (2007). Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular Cancer Therapeutics. 6(12). 3314–3322. 513 indexed citations breakdown →

19.

Zou, Helen Y., Qiuhua Li, Joseph H. Lee, et al.. (2007). An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms. Cancer Research. 67(9). 4408–4417. 593 indexed citations breakdown →

20.

Patrick, C., Ramasamy Jagadeeswaran, Simha Jagadeesh, et al.. (2005). Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer. Cancer Research. 65(4). 1479–1488. 467 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact